Role of Cytokines in Allergic Airway Inflammation

Hiroshi Nakajima\textsuperscript{a} Kiyoshi Takatsu\textsuperscript{b}

\textsuperscript{a}Department of Molecular Genetics, Graduate School of Medicine, Chiba University, Chiba, and
\textsuperscript{b}Division of Immunology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Key Words
Cytokines \cdot Th1 cells \cdot Th2 cells \cdot Airway inflammation

Abstract
Asthma is characterized by intense infiltration of eosinophils and CD4+ T cells into the submucosal tissue of airways. Accumulating evidence indicates that T helper type 2 cell-derived cytokines such as interleukin (IL)-4, IL-5 and IL-13 play critical roles in orchestrating and amplifying allergic inflammation in asthma. In addition, it has been suggested that newly identified cytokines including thymic stromal lymphopoietin, IL-25 and IL-33 are involved in the induction of allergic inflammation in asthma. In this review, we discuss the role of individual cytokines in the pathogenesis of asthma.

Copyright © 2007 S. Karger AG, Basel

Introduction
Immediate hypersensitivity allergic reactions are dependent on degranulation of activated mast cells and peak within 30 min. Over the subsequent several hours, the late-phase allergic reaction (LAR) evolves, peaks at 6–12 h and may persist for several days. In contrast to the immediate hypersensitivity reaction in which histologic findings are predominantly edema and vasodilatation, the LAR is characterized by a prominent leukocytic infiltrate comprised of eosinophils, T helper (Th) 2 cells and neutrophils [1–3].

Role of Classical Th2 Cytokines in Causing Allergic Inflammation

Interleukin-4
Allergic diseases including asthma are characterized by inflammation with pronounced infiltration of eosinophils [1–3]. An essential biological activity of IL-4 in the development of allergic inflammation is to drive the differentiation of naive Th0 cells into Th2 cells, which secrete IL-4, IL-5, IL-9 and IL-13 but not interferon (IFN)-γ [4, 5]. Studies using IL-4-deficient mice clearly showed that IL-4 was required for the development of allergic inflammation, as antigen-induced allergic inflammation was significantly decreased in IL-4-deficient mice as compared with wild-type mice [6]. Coyle et al. [7] also...
demonstrated that the administration of neutralizing anti-IL-4 antibody prior to antigen immunization prevented the development of antigen-induced airway inflammation, whereas the administration of the same antibody after immunization but prior to antigen inhalation was not effective for preventing antigen-induced airway inflammation. These studies suggest that while IL-4 is essential for the initial differentiation and/or expansion of antigen-specific Th2 cells, IL-4 may not be essential for the induction of allergic airway inflammation at an effector phase. On the other hand, some studies have indicated the importance of IL-4 in promoting allergic inflammation at an effector phase by inducing the recruitment of Th2 cells in part via vascular cell adhesion molecule-1/very late antigen-4-dependent mechanisms [8, 9]. In addition, a clinical trial of soluble IL-4 receptor (IL-4R) that neutralizes IL-4 function showed the therapeutic benefit in moderately severe asthma [10]. Therefore, IL-4 could play a role in the induction of allergic inflammation in a sensitized individual, but the relative importance of IL-4 depends on the state of sensitization and/or genetic background.

**Interleukin-5**

IL-5 has been originally defined as a T cell-derived cytokine that triggers activated B cells for a terminal differentiation into immunoglobulin-producing cells [11]. Concurrently, IL-5 has been recognized as the major maturation and differentiation factor for eosinophils [12, 13]. It has been demonstrated that the expression of IL-5 mRNA in bronchial biopsies of asthmatic patients is increased as compared with healthy volunteers and that the predominant source of IL-5 mRNA is CD4+ T cells [14]. Indeed, CD4+ T cell activation in asthma is accompanied by increased serum concentrations of IL-5 [15]. IL-5 mRNA and protein are also found in mast cells located within allergen-challenged tissues. Based on these observations, an attractive paradigm for eosinophil involvement in the LAR is (1) the upregulation of IL-5 synthesis by mast cells activated in an immediate hypersensitivity allergic reaction, resulting in (2) eosinophil recruitment and activation [1–3]. Concomitantly, (3) CD4+ T cells are recruited by other inflammatory mediators of the allergic reaction and undergo antigen-specific activation and acquisition of the Th2 phenotype which (4) further enhances eosinophil recruitment and activation.

Animal models further support a role for IL-5 in the induction of eosinophilic inflammation in allergies and asthma. It has been shown that the enforced expression of IL-5 by transgene causes eosinophilia [16–18]. A pivotal role for IL-5 in the late asthmatic response has been confirmed by the capacity for neutralizing anti-IL-5 monoclonal antibody (mAb) to inhibit antigen-induced airway hyperresponsiveness and eosinophil infiltration in the airways of mice and guinea pigs [19–21]. Importantly, administration of neutralizing anti-IL-5 mAb reduced airway eosinophilia when administered within hours preceding respiratory antigen challenge or when administered up to 5 days after antigen challenge. The lack of bronchial hyperreactivity and eosinophilia in the lungs of antigen-sensitized and antigen-challenged IL-5-deficient and IL-5R α chain (IL-5R α)-deficient mice further demonstrated the importance of IL-5 in allergic airway inflammation [22–25].

Results of humanized anti-IL-5 mAb treatment in patients with mild asthma confirmed the importance of IL-5 in eosinophilic inflammation in human [26]. However, anti-IL-5 antibody did not reduce asthmatic symptoms and airway reactivity [26], suggesting that airway hyperresponsiveness occurs independently of IL-5 and airway eosinophilia. Recently, the role of IL-5 and eosinophils in the development of airway remodeling, in an experimental model of chronic asthma, has been carefully studied by using mice lacking IL-5R α or mice transgenic for IL-5 [27]. The study has demonstrated that IL-5 plays an obligatory role in the airway remodeling observed in experimental asthma [27]. Intriguingly, treatment of wild-type mice with anti-IL-5 antibody almost completely prevented subepithelial and peribronchial fibrosis caused by antigen inhalation [27]. Importantly, anti-IL-5 antibody treatment has also been shown to improve airway remodeling in asthmatic patients [28, 29]. Further studies are required to define the mechanism underlying IL-5 and eosinophil-mediated airway remodeling in asthma. It may be worthwhile to test the feasibility of humanized anti-IL-5R α antibody in a monkey asthma model for eliminating eosinophils localized in the airways by antibody-dependent cell-mediated cytotoxicity.

**Interleukin-13**

Accumulating evidence suggests that IL-13 plays a key role in the allergic response via its actions on epithelial and smooth muscle cells and not through traditional effector pathways involving eosinophils and immunoglobulin E (IgE)-mediated events [30–32]. The importance of IL-13 was evidenced by the finding that neutralization of endogenously released IL-13 with a soluble form of IL-13R α2, which binds IL-13 but not IL-4, during antigen exposure largely inhibited the characteristics of asthma in murine asthma models [33, 34]. In addition, antigen...
challenge of IL-13-deficient mice failed to elicit airway hyperresponsiveness and mucus production despite the continued presence of IL-4 and IL-5 and airway inflammation [35]. Its importance as an effector molecule in asthma was further evidenced by the finding that acute administration of IL-13 itself was sufficient to recapitulate many features of airway responses characterized in asthma, such as eosinophilic inflammation, mucus hyperproduction and airway hyperresponsiveness in mice [33, 34]. Moreover, lung-specific expression of IL-13 resulted in the development of characteristic features of asthma [36]. These results suggest that IL-13, independent from other Th2 cytokines, is necessary and sufficient to induce key features of allergic inflammation at an effector phase. Importance of IL-13 in asthma was also supported by strong associations between genetic polymorphisms in the IL-13 gene and asthma [37]. The role of IL-13 in the pathogenesis of asthma has been described in more detail in recent reviews [30–32].

**Interleukin-9**

Another Th2 cell-derived cytokine that seems involved in the pathogenesis of asthma is IL-9 [38]. First, genetic analyses revealed the possible involvement of IL-9 in causing airway hyperresponsiveness [39]. In addition, it has been demonstrated that the expression of IL-9 is increased in bronchial biopsy samples of asthmatics [40]. Lung-specific overexpression of IL-9 by transgene has also been shown to induce airway hyperresponsiveness in addition to morphological changes that bear similarities to asthma [41]. Neutralizing antibodies against IL-9 further demonstrate a crucial role for IL-9 in the development of the allergic asthmatic response [42]. On the other hand, although IL-9 plays a role in goblet cell hyperplasia and mast cell development, experiments analyzing IL-9-deficient mice show that it has little or no effect on eosinophils, T cell development or immunoglobulin response [43]. Further study is required for clarifying the role of IL-9 in the regulation of allergic airway inflammation.

**Role of Th1 Cytokines in the Regulation of Allergic Airway Inflammation**

**Interferon-γ**

IFN-γ, the principal Th1 effector cytokine, has been shown to be crucial for the resolution of allergic inflammation. Using murine asthma models, IFN-γ has been shown to prevent the development of antigen-induced airway eosinophilia and hyperresponsiveness [44, 45]. It has also been shown that IFN-γ receptor (IFN-γR)-deficient mice exhibit a prolonged airway eosinophilia in response to allergen inhalation [46]. In accordance with these findings, we found that mice lacking T-bet, the master regulator of Th1 cell development and IFN-γ production [5], exhibited enhanced antigen-induced allergic airway inflammation [Fujiwara et al., submitted]. These results suggest that IFN-γ could counterbalance Th2 cell-mediated allergic airway inflammation. On the other hand, some studies have shown that the coexistence of Th1 cells aggravates the Th2 cell-mediated allergic responses [47–49]. Using cell transfer experiments, it has been shown that allergen-specific Th1 cells enhance Th2 cell-mediated asthmatic airway responses [47–49], presumably by inducing the production of tumor necrosis factor (TNF-α) and subsequent vascular cell adhesion molecule-1 expression at the inflamed site [49]. Because IFN-γ itself potently inhibits Th2 cell activation [4, 5] and allergic airway inflammation [44, 45], it is suggested that the balance between IFN-γ and TNF-α produced by activated Th1 cells may be a key determinant of the role of Th1 cells in the regulation of allergic airway inflammation.

**Interleukin-12**

IL-12 is produced by antigen-presenting cells such as dendritic cells (DCs) and macrophages and is known to play an important role in Th1 differentiation during primary antigen presentation [50]. In asthmatic individuals, it has been shown that IL-12 expression is reduced in bronchial biopsy samples [51]. In addition, murine asthma models have confirmed that exogenous administration of IL-12 during the primary sensitization suppresses allergen-induced Th2 development and subsequent allergic inflammation [52]. Interestingly, even when IL-12 is administered only during antigen challenge, IL-12 retains the capacity to inhibit allergen-induced allergic inflammation and airway hyperresponsiveness [52, 53]. Because fully differentiated Th2 cells have been shown to lose IL-12 responsiveness [54], a reversal of Th2 cells towards a Th1 phenotype at this stage seems unlikely. IL-12 may suppress Th2 cell-mediated allergic inflammation by augmenting the production of IFN-γ from coexisting Th1 cells, CD8+ T cells or natural killer cells.

**Interleukin-18**

IL-18 was initially described as IFN-γ-releasing factor [55]. Consistent with this finding, the absence of endogenous IL-18 in IL-18-deficient mice resulted in enhanced
antigen-induced airway eosinophilia [56]. In addition, IL-12 and IL-18 act synergistically in inducing IFN-γ production and inhibit IL-4-dependent IgE synthesis and allergen-induced airway hyperresponsiveness [57]. These results suggest that IL-18 functions as a negative regulator for allergic inflammation. On the other hand, it has recently been shown that Th1 cells come to produce a large amount of Th2 cytokines such as IL-9 and IL-13 and robust IFN-γ and TNF-α when stimulated with antigen plus IL-18, while Th1 cells do not produce IL-9 and IL-13 and produce less amounts of IFN-γ and TNF-α when stimulated with antigen in the absence of IL-18 [58]. Moreover, when Th1 cell-transferred mice are challenged with antigen and IL-18, mice develop severe airway inflammation characterized by massive infiltration of eosinophils as in the antigen-challenged Th2 cell-transferred mice [58]. Furthermore, we have demonstrated that the administration of IL-18 enhances antigen-induced eosinophil recruitment into the airways of sensitized mice in part by increasing antigen-induced TNF-α production [59]. Thus, it is suggested that the function of IL-18 depends on the environmental cytokines [60]. Further study is needed to address the molecular basis for the pleiotrophic function of IL-18.

Interleukin-27

IL-27, an IL-12-related cytokine with pro- and anti-inflammatory properties, is composed of p28 subunit and EBI3 [61]. The cells responsible for IL-27 production are DCs and macrophages [61]. IL-27R is composed of gp130 and WSX1, which was known as an orphan receptor that induces Th1 cell differentiation [61]. An early study has indicated that IL-27 functions as a proinflammatory cytokine because it synergizes with IL-12 to promote Th1 responses [61]. Th1 deviation by IL-27 is due in part to the induction of T-bet [62]. A recent study has also shown that addition of IL-27 to naive T cells under Th2-polarizing conditions decreases the expression of GATA-3, a master regulator for Th2 development, and thus IL-4 production [63]. Consistent with these findings, ovalbumin-challenged WSX1-deficient mice showed a marked enhancement of Th2 cytokine production, eosinophil infiltration into the airway, and airway hyperresponsiveness with goblet cell hyperplasia [64], suggesting that IL-27 functions as a negative regulator of Th2-type immune responses in vivo. Interestingly, IFN-γ production was also enhanced in WSX1-deficient mice [64]. Therefore, these results suggest that the enhanced allergic responses in WSX1-deficient mice seem to be independent from the Th1-promoting property of IL-27.

Proinflammatory Cytokines in the Allergic Inflammation

IL-17 Family Cytokines

The original member of the IL-17 family, IL-17A, was identified in 1995, and subsequently, 5 cytokines, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25) and IL-17F, were identified as IL-17 family cytokines [65]. IL-17A and IL-17F are mainly expressed in a recently identified subpopulation of CD4+ T cells, namely Th17 cells, which are believed to be involved in the pathogenesis of autoimmune diseases [66]. Both IL-17A and IL-17F induce the expression of a variety of cytokines and chemokines including IL-6, granulocyte macrophage colony-stimulating factor and CXCL10 from epithelial and vascular endothelial cells and induce IL-8 from fibroblasts [65, 67, 68]. The ability of IL-17A and IL-17F to evoke migration of neutrophils but not of eosinophils makes it likely that these cytokines are involved in severe asthma, in which accumulation of neutrophils in the airways is a hallmark of disease [69]. Because IL-17 and IL-17F are expressed in the airway of asthmatic patients [67], these cytokines may constitute a link between the activation of T cells and recruitment of neutrophils into the airways.

IL-25 is produced by activated Th2 cells [70] and mast cells [71]. The in vivo and in vitro biological activities of IL-25 are markedly different from those described for IL-17 and other IL-17 family cytokines [65, 70, 72, 73]. Systemic administration of IL-25 protein [70] or the systemic expression of IL-25 by transgene [73] induces the production of IL-4, IL-5 and IL-13 from undefined non-T/non-B cells and the resultant Th2-type immune responses including blood eosinophilia, increased serum IgE levels and pathological changes in the lung and other tissues. We also found that IL-25 mRNA was expressed in the lung upon antigen inhalation and that neutralization of endogenously produced IL-25 by soluble IL-25R decreased antigen-induced eosinophil and CD4+ T cell recruitment into the airways [74]. In addition, we found that although the enforced expression of IL-25 in the lung itself failed to induce allergic airway inflammation, the expression of IL-25 significantly enhanced antigen-induced eosinophil and Th2 cell recruitment in the airways [74]. Moreover, IL-25-induced enhancement of antigen-induced eosinophil recruitment into the airways was inhibited by the depletion of CD4+ T cells [74]. These findings indicate that IL-25 plays an important role in enhancing antigen-induced allergic airway inflammation by amplifying a Th2 cell-dependent pathway. Furthermore, the enhanced expression of IL-25 in the airway of
膿性気管支過敏の関与の可能性を示すことが示され、IL-25の関与を示唆する可能性が示された。IL-25は、抗allergenの治療を目的とした新しいアプローチの1つであり、異常な免疫応答を抑制し、アレルギー疾患の治療に使われる可能性がある。
tory cells to the sites. Indeed, mice expressing IL-31 in skin showed an increase in the number of lesions with an inflammatory cell infiltrate similar to that observed in atopic dermatitis [94]. In addition, it has been demonstrated that activated leukocytes in patients with atopic dermatitis expressed significantly higher IL-31 levels as compared with control subjects [95, 96]. The possible involvement of IL-31 in allergic airway inflammation warrants further investigation in light of these early findings.

Interleukin-33
ST2 is an IL-1R-related protein expressed on Th2 cells and mast cells [97]. ST2 has been shown to function as an important effector molecule of Th2 responses in a number of experimental settings including mouse asthma models [98–100]. Recently, an IL-1-like cytokine, IL-33, has been identified as a ligand for ST2 [101]. It has been demonstrated that IL-33 is produced by many cell types including smooth muscle cells, epithelial cells and DCs and drives production of IL-5 and IL-13 from in vitro polarized Th2 cells [101]. These findings suggest that IL-33/ST2 interaction may play a significant role in the induction of allergic airway inflammation.

Conclusion
There is overwhelming evidence to support a major role for T cells, especially Th2 cells, and their cytokines in asthma (fig. 1). In addition to classical Th2 cytokines such as IL-4, IL-5, IL-9 and IL-13, other cytokines derived from Th2 cells, including IL-25 and IL-31, have also been shown to play an important role in causing allergic inflammation. Non-lymphoid cell-derived cytokines such as IL-33 and TSLP are also involved in the induction of allergic inflammation through the induction of Th2 cell differentiation. Further studies identifying relative importance of these cytokines in asthmatic patients are needed to uncover therapeutic targets for asthma.
Cytokines in Allergic Airway Inflammation

References


Linden A: Role of interleukin-17 and the neutrophil in asthma. Int Arch Allergy Immunol 2001;126:179–184.


Inflammation

Cytokines in Allergic Airway Inflammation


